Equity Profile

BIO

Bio-Rad Laboratories, Inc.

Health CareLife Sciences Tools & Services$8.0B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Bio-Rad Laboratories, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's ability to expand its market presence and drive sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BIO Q2-2026 Earnings Preview

Context

Company Snapshot

Bio-Rad Laboratories, Inc. is a leading company in the health care sector, specializing in life sciences tools and services. Their products are essential for research and clinical diagnostics, making them significant players in the ongoing advancements in health care and biotechnology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

In Q1-2026, Bio-Rad reported an EPS of $1.89, missing estimates by 31.77%. The stock reacted positively, gaining 1.81% the following day despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has missed earnings estimates in the last quarter. Investors are cautious about how the company will perform this quarter.

Bull Case

If Bio-Rad can demonstrate strong revenue growth and improved margins, it could regain investor confidence and drive the stock higher.

Bear Case

Continued earnings misses and weak revenue growth could lead to further declines in stock price, especially given the recent performance trends.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to the previous quarter?

Given the significant miss last quarter, the market will be closely watching for any signs of recovery in earnings.

How is revenue growth trending, especially in key product segments?

Revenue growth is crucial for assessing the company's market position and future potential, especially after recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Bio-Rad to rebound from its recent earnings miss, as historical performance shows that recovery can happen quickly.

Supporting Evidence

Options are pricing a 17.11% move, indicating expectations of volatility that may not align with the company's actual performance.

The recent stock reaction to earnings misses has been relatively muted, suggesting that the market may be overly cautious.

The company has a history of bouncing back from earnings misses, which could be overlooked in current sentiment.

Key Risk

If the EPS comes in above $2.00, it could shift the narrative significantly and challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining whether Bio-Rad can stabilize its earnings and regain investor trust.

Bull Confirmed If

A return to an EPS of at least $2.50 would signal a recovery in profitability and investor confidence.

Bear Confirmed If

An EPS below $1.80 would confirm ongoing struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±17.11%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±17.1% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

58.0%

Calls (2K)P/C Ratio: 0.33Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests the stock could see a modest increase, confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may remain flat as investors weigh future prospects.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.97%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on revenue growth in key product segments.
2Management's outlook on future earnings guidance.
3Details on cost management strategies and their impact on margins.
4Insights into market demand for Bio-Rad's products.
5Any changes in competitive landscape or market share.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Bio-Rad Laboratories, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's ability to expand its market presence and drive sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

In Q1-2026, Bio-Rad reported an EPS of $1.89, missing estimates by 31.77%. The stock reacted positively, gaining 1.81% the following day despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has missed earnings estimates in the last quarter. Investors are cautious about how the company will perform this quarter.

Bull Case

If Bio-Rad can demonstrate strong revenue growth and improved margins, it could regain investor confidence and drive the stock higher.

Bear Case

Continued earnings misses and weak revenue growth could lead to further declines in stock price, especially given the recent performance trends.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to the previous quarter?

Given the significant miss last quarter, the market will be closely watching for any signs of recovery in earnings.

How is revenue growth trending, especially in key product segments?

Revenue growth is crucial for assessing the company's market position and future potential, especially after recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Bio-Rad to rebound from its recent earnings miss, as historical performance shows that recovery can happen quickly.

Supporting Evidence

Options are pricing a 17.11% move, indicating expectations of volatility that may not align with the company's actual performance.

The recent stock reaction to earnings misses has been relatively muted, suggesting that the market may be overly cautious.

The company has a history of bouncing back from earnings misses, which could be overlooked in current sentiment.

Key Risk

If the EPS comes in above $2.00, it could shift the narrative significantly and challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining whether Bio-Rad can stabilize its earnings and regain investor trust.

Bull Confirmed If

A return to an EPS of at least $2.50 would signal a recovery in profitability and investor confidence.

Bear Confirmed If

An EPS below $1.80 would confirm ongoing struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±17.11%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±17.1% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

58.0%

Calls (2K)P/C Ratio: 0.33Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests the stock could see a modest increase, confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may remain flat as investors weigh future prospects.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.97%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on revenue growth in key product segments.
2Management's outlook on future earnings guidance.
3Details on cost management strategies and their impact on margins.
4Insights into market demand for Bio-Rad's products.
5Any changes in competitive landscape or market share.